23andMe Holding Co.

NASDAQ:MEUnited States

23andMe Holding Co. is a genetics-led consumer healthcare and biopharmaceutical company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.

Contact Information

Headquarters

349 Oyster Point BoulevardSOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-938-6300

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer, Co-Founder

Anne Wojcicki

Chief Financial and Accounting Officer

Joe Selsavage

Lead Independent Director

Mark Jensen

Independent Director

Andre Fernandez

Independent Director

Jim Frankola